Single-cell technologies and spatial transcriptomics: decoding immune low - response states in endometrial cancer

Abstract

Globally, endometrial cancer continues to impact a significant number of women. Immunotherapy provides those suffering from advanced or relapsed disease hope, but an important barrier is still the absence of trustworthy predictive biomarkers. To tackle this challenge, single-cell sequencing and spatial transcriptomics (ST) are increasingly applied. In cervical cancers of the no specific molecular profile (NSMP) subtype accompanied by p53 mutations. In many cases, the tumor microenvironment (TME) in endometrial cancer exhibits strong immunosuppression or poor immune cell infiltration, often leading to worse clinical outcomes. Single-cell sequencing reveals cellular heterogeneity and helps identify potential therapeutic targets and predict treatment responses. Conversely, ST assists in determining biomarkers that influence the effectiveness of immunotherapy by capturing the spatial organization of tumors. When combined, these technologies allow for integrated multi-omics analysis that aids in the development of immunotherapies, prognostication, and diagnosis. But there are still moral and legal issues. Clinicians may be able to improve outcomes for patients who don’t respond well to current immunotherapies by utilizing these combined approaches.